The place of eluxadoline in the management of irritable bowel syndrome with diarrhea
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Amo...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-09-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756283X17721152 |
| _version_ | 1818454711016095744 |
|---|---|
| author | Sherry Levio Brooks D. Cash |
| author_facet | Sherry Levio Brooks D. Cash |
| author_sort | Sherry Levio |
| collection | DOAJ |
| description | Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing. Management of IBS typically begins with dietary and lifestyle modifications, progressing to over-the-counter therapies, and then to prescription medications, both approved and nonapproved for IBS. This narrative summarizes the efficacy and safety of three US Food and Drug Administration (FDA)-approved prescription therapies for IBS with diarrhea (IBS-D), with a focus on the most recently marketed agent, eluxadoline, and its role in the treatment IBS-D. |
| first_indexed | 2024-12-14T21:59:13Z |
| format | Article |
| id | doaj.art-e1cfcd50e49241dfb954d89fcf26e0e8 |
| institution | Directory Open Access Journal |
| issn | 1756-283X 1756-2848 |
| language | English |
| last_indexed | 2024-12-14T21:59:13Z |
| publishDate | 2017-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-e1cfcd50e49241dfb954d89fcf26e0e82022-12-21T22:46:02ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X1756-28482017-09-011010.1177/1756283X17721152The place of eluxadoline in the management of irritable bowel syndrome with diarrheaSherry LevioBrooks D. CashIrritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing. Management of IBS typically begins with dietary and lifestyle modifications, progressing to over-the-counter therapies, and then to prescription medications, both approved and nonapproved for IBS. This narrative summarizes the efficacy and safety of three US Food and Drug Administration (FDA)-approved prescription therapies for IBS with diarrhea (IBS-D), with a focus on the most recently marketed agent, eluxadoline, and its role in the treatment IBS-D.https://doi.org/10.1177/1756283X17721152 |
| spellingShingle | Sherry Levio Brooks D. Cash The place of eluxadoline in the management of irritable bowel syndrome with diarrhea Therapeutic Advances in Gastroenterology |
| title | The place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| title_full | The place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| title_fullStr | The place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| title_full_unstemmed | The place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| title_short | The place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| title_sort | place of eluxadoline in the management of irritable bowel syndrome with diarrhea |
| url | https://doi.org/10.1177/1756283X17721152 |
| work_keys_str_mv | AT sherrylevio theplaceofeluxadolineinthemanagementofirritablebowelsyndromewithdiarrhea AT brooksdcash theplaceofeluxadolineinthemanagementofirritablebowelsyndromewithdiarrhea AT sherrylevio placeofeluxadolineinthemanagementofirritablebowelsyndromewithdiarrhea AT brooksdcash placeofeluxadolineinthemanagementofirritablebowelsyndromewithdiarrhea |